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Antitumour responses induced by a cell-
based Reovirus vaccine in murine lung and
melanoma models
Ciorsdan A. Campion1,2*, Declan Soden1 and Patrick F. Forde1
Abstract
Background: The ever increasing knowledge in the areas of cell biology, the immune system and the mechanisms
of cancer are allowing a new phase of immunotherapy to develop. The aim of cancer vaccination is to activate the
host immune system and some success has been observed particularly in the use of the BCG vaccine for bladder
cancer as an immunostimulant. Reovirus, an orphan virus, has proven itself as an oncolytic virus in vitro and in vivo.
Over 80 % of tumour cell lines have been found to be susceptible to Reovirus infection and it is currently in phase
III clinical trials. It has been shown to induce immune responses to tumours with very low toxicities.
Methods: In this study, Reovirus was examined in two main approaches in vivo, in mice, using the melanoma
B16F10 and Lewis Lung Carcinoma (LLC) models. Initially, mice were treated intratumourally (IT) with Reovirus and
the immune responses determined by cytokine analysis. Mice were also vaccinated using a cell-based Reovirus
vaccine and subsequently exposed to a tumourigenic dose of cells (B16F10 or LLC). Using the same cell-based
Reovirus vaccine, established tumours were treated and subsequent immune responses and virus retrieval
investigated.
Results: Upregulation of several cytokines was observed following treatment and replication-competent virus
was also retrieved from treated tumours. Varying levels of cytokine upregulation were observed and no
replication-competent virus was retrieved in vaccine-treated mice. Prolongation of survival and delayed tumour growth
were observed in all models and an immune response to Reovirus, either using Reovirus alone or a cell-based vaccine
was also observed in all mice.
Conclusion: This study provides evidence of immune response to tumours using a cell-based Reovirus vaccine in both
tumour models investigated, B16F10 and LLC, cytokine induction was observed with prolongation of survival in almost
all cases which may suggest a new method for using Reovirus in the clinic.
Keywords: Reovirus, Immune, Cytokine, Cancer Vaccine
Background
Rapidly growing, aggressive tumours continue to be a
major challenge to current treatment protocols. Both
melanoma and lung carcinomas often demonstrate poor
prognosis and metastasise rapidly making therapy even
more of a challenge [1]. The American Cancer Society
estimates that 135,000 people in the US are diagnosed
annually with melanoma and approximately 50 % of
these will be invasive at the time of diagnosis. While
melanoma is by no means the most common skin cancer
diagnosed, it is responsible for the most deaths [2]. Over
50 % of lung cancers have already metastasised at the
time of diagnosis and 5-year survival at this stage is less
than 5 %. Overall, lung cancers are responsible for 20 %
of all cancer deaths worldwide (WHO) [3]. Models
reflecting these two aggressive tumour types were inves-
tigated in this study.
Traditionally, oncolytic viruses are self-replicating and
tumour selective viruses which will not produce disease
in the host [4]. Respiratory Enteric Orphan Virus or
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Reovirus is a non-pathogenic virus initially isolated from
human respiratory and gastrointestinal tracts in the 1950s
[5, 6]. Reovirus is not associated with any known disease
and has been shown to induce apoptosis in cells carrying
a mutation in a certain pathway, the Ras pathway, which
is found in a wide variety of tumour types [7, 8]. In vitro,
over 80 % of cell lines of tumour origin tested have been
found to be susceptible to Reovirus-related oncolysis [9].
Reovirus as a cancer therapy was approved for clinical
trials by the FDA as Reolysin® with the first phase I study
conducted in 2002 in patients with a variety of malig-
nancies [10]. Several phase II and III studies have since
been conducted in a wide range of malignancies, investi-
gating Reovirus alone and in combination with current
treatment modalities [11, 12]. The majority of trials
currently underway are investigating the combination
of Reolysin® with existing chemotherapy agents such
as carboplatin and paclitaxel [13].
Cancer vaccination is an area of cancer therapy that
has been in development for many years with several
approaches being developed. The aim of vaccination in
cancer therapy is to activate the host immune system. The
most straightforward method of vaccine development is
to select antigens that are expressed on the tumour –
tumour associated antigens – such as p53 [14].
Oncolytic viruses are ideal candidates in the role of
cancer vaccination due to their tumour-selective nature
and the means by which they induce cell death provides
a natural selection of tumour-associated antigens (TAAs)
[15, 16]. Several strategies have been or are currently
being investigated in an effort to amplify the cancer
vaccination role of oncolytic viruses including genetic
manipulation to express additional proteins such as Heat
Shock Proteins (HSPs), cytokines and chemokines. Clin-
ically, a poxvirus expressing GM-CSF (Pexa-Vec) dem-
onstrated antitumour immunity in several phase I/II
trials and was also shown to be capable of inducing
antibody-mediated cancer cell lysis. Similarly, adenovirus
expressing several HSPs proved to be capable of indu-
cing tumour antigen-specific CD8+ T cell responses in
melanoma and colorectal cancer [17–21]. Figove et. al,
have previously investigated the potential of Reovirus in
a vaccine role in a HPV16 transformed murine model
with some delay in tumour development observed how-
ever survival was not reported [22].
In this study, mouse models were administered a cell-
based Reovirus vaccine as a prophylaxis vaccine and
their ability to withstand subsequent challenges observed.
This cell-based Reovirus vaccine was also investigated as a
therapeutic vaccine in the murine models B16F10 and
Lewis Lung Carcinoma (LLC). Immune responses
were also explored as the role of the immune system
becomes ever more important in the effective treatment
of cancer [23].
Methods
Virus propagation and quantification
Reovirus Type 3 Dearing (T3D) was obtained from The
National Collection of Pathogenic Viruses (Public Health
England). Virus was propagated and plaque assayed on
L929 cells (mouse fibroblast). Confluent flasks of L929
were infected with Reovirus T3D with the virus allowed
to adsorb for approximately 1h at 37 °C in a humidified
atmosphere containing 5 % CO2 in air. Following incu-
bation the viral inoculum was removed and fresh
medium added and cells were incubated for 48h. The
medium was then collected and cell debris removed by
centrifugation (140g for 10mins).
This clarified supernatant was then plaque assayed to
determine the viral titre. 6-well plates were seeded with
L929 cells and allowed to become 100 % confluent.
10-fold serial dilutions of the virus were performed
and 400μl of each dilution were plated in duplicate in
wells of 6 well plates containing the L929 monolayers.
The inoculum was allowed to adsorb for 1h at 37 °C
in a humidified atmosphere containing 5 % CO2. Fol-
lowing adsorption, the inoculum was removed and
2ml of overlay medium, 1:1 2 % agar:2xMinimum Es-
sential Medium (MEM) containing 0.8 % Foetal Calf
Serum, 0.4 % L-glutamine and 0.2 % penicillin/
streptomycin, were added to well. The overlayed
monolayers were allowed stand at room temperature
until the overlay had solidified. The plates were incubated
at 37 °C in a humidified atmosphere containing 5 % CO2
for 72h. Following 72h incubation, the monolayers were
fixed with 10 % formylsaline (formaldehyde in phosphate
buffered saline (PBS)) for 45 min to 1h at room
temperature. The agar overlay was then carefully removed
and the monolayers stained with 2 % crystal violet (crystal
violet in 96 % ethanol) for 10 mins. The monolayers were
then gently washed in water. Plaques appear as clear areas
on a purple background.
Cell culture
The tumour cell lines B16F10 and Lewis Lung Carcinoma
(LLC) were obtained from the American Type Cell Collec-
tion (Manassas, VA). Both cell lines were grown in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma
Aldrich) supplemented with 10 % v/v Foetal Calf Serum
(Gibco) and 1 % v/v 20X L-glutamine (Sigma Aldrich).
Cells were maintained at 37°C in a humidified atmosphere
containing 5 % CO2 in air.
Animals and tumour induction
For both B16F10 and LLC experiments, C57Bl/6j mice
(Harlan Laboratories, UK), approximately 6–8 weeks old
were used. The mice were kept in a pathogen free envir-
onment for at least one week prior to experiments. For
routine tumour inoculation, cells were harvested from
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tissue culture flasks by trypsinisation and counted using
a haemocytometer. For tumour induction of B16F10
tumours, 5 × 105 cells were resuspended in 200μl of
serum-free DMEM. LLC tumours were induced using
2 × 105 cells resuspended in 200μl of serum-free DMEM.
Tumour inoculation was performed subcutaneously
(s.c.) into the right flank. Following establishment, the
tumours were measured using vernier callipers, in two
dimensions. Tumour volume was calculated using the
formula V = ab2π/6 where a is the longest diameter of
the tumour and b is the longest diameter perpendicular
to a. Mice were humanely euthanized by cervical
dislocation when tumour volume reached 1.5cm2.
Virus purification
For administration of Reovirus intratumourally, virus
was initially pelleted using ultracentrifugation. Appropri-
ate aliquots of virus were centrifuged at 28,400 × g for
1h using Beckman Coulter Polyallomer centrifuge tubes.
The virus pellets were then resuspended in serum-free
DMEM.
Cell-based Reovirus vaccine
B16F10 and LLC cells were infected at an MOI of 10 PFU/
cell. Following an adsorption period of 1 h, the virus inocu-
lum was removed, fresh medium added and the cells incu-
bated overnight at 37 °C. After overnight incubation, the
cells were trypsinised, washed twice with PBS and counted.
For B16F10 based vaccine, 5 × 106 cells were considered a
vaccine dose while 2 × 106 cells were used for LLC vaccin-
ation. Viable cells were present in each vaccine dose as
determined by colony formation assay (data not shown).
Virus administration and vaccination regimen
Resuspended virus for IT administration was injected IT
in an escalating dose regimen over a three week period.
Two doses of virus were administered in every treatment
week.
Week 1; 1 × 107 PFU; Week 2; 1 × 108 PFU and Week
3; 1 × 109 PFU
A cell based vaccination was administered by two
main approaches; as a prophylactic vaccine and as a
therapy for established tumours (Fig. 1). For prophylaxis,
naïve mice were inoculated s.c. with the vaccine as
Fig. 1 Schematic representation of the vaccination regime. a Regime of cell-based Reovirus vaccine as a prophylactic and (b) as a therapeutic for
established tumours
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prepared above. 8–12 weeks following vaccination, mice
were inoculated with a tumourigenic dose of the appro-
priate cell line (B16F10 or LLC). Tumour volume was
measured as indicated previously. For a therapeutic
approach, tumours were induced in mice as indicated
previously in C57Bl/6j mice. When tumours became
palpable, treatment was administered by means of a vac-
cination s.c. on the opposite flank to the tumour or
intravenously (IV) via the tail vein. Tumour volume was
measured as indicated.
In vitro cytotoxicity assay and adoptive transfer of
splenocytes
Splenocytes were harvested from mice previously vacci-
nated and challenged and from naïve mice. 2 × 106 sple-
nocytes were incubated with 2 × 105 mitomycin-C
treated target cells in the presence of 25IU/ml IL-2 with
both sets of experiments (vaccinated and naïve) being
performed in triplicate. The splenocyte/cell mixtures
were incubated for 5 days at 37 °C in a humidified
atmosphere containing 5 % CO2 in air and following in-
cubation the lymphoid cells were harvested. The cells
were washed three times with serum-free DMEM, to en-
sure any remaining lymphoid cells were removed, and
applied as effectors in effector:target ratios of 20:1 and
1:1 with 2×104 target cells. The cells were incubated
overnight in round bottomed 96 well plates. Wells were
washed five times with PBS and an MTT assay was per-
formed to quantify remaining living cells. 200μl of MTT
solution (2mg/ml in serum-free DMEM) were added to
each well. The plate was then incubated at 37 °C in a
humidified atmosphere containing 5 % CO2 in air for
4h. Following incubation, the MTT was removed by
aspiration and 200μl of DMSO added to each well. The
plate was shaken for 2–3 min and the absorbance for
each well at OD570nm was measured.
Immune-mediated anti-tumour responses following
vaccination were investigated using a modified Winn
assay. Splenocytes were harvested from mice previously
vaccinated and challenged and naïve mice. Splenocytes
were then mixed with the target cell (B16F10/LLC) in a
ratio of 50:1. Following 48h incubation, the splenocyte/
cell mixture was injected s.c. into naïve mice at a
tumourigenic dose for each particular cell line. Mice
were monitored for tumour development
Cytokine analysis
Excised tumours were lysed by homogenisation in RIPA
buffer (Sigma Aldrich) (with proteinase inhibitors).
Lysates were then tested on a multiplex mouse Th1/
Th2 multi-spot assay as per manufacturer’s protocol
(MesoScale Discovery). Briefly, the level of protein
was normalised using a Bio-Rad protein assay (data
not shown) and a protein level of 50–100μg/25μl was
used. 25μl of each lysate was plated in triplicate and
incubated overnight at 4 °C with shaking. The wells
were then washed three times in PBS-0.05 % Tween
20. 25μl of detection antibody was added to each well
and the plate was incubated at room temperature for
2h with shaking. The wells were washed three times
in PBS-0.05 % Tween 20 and 150μl of read buffer
was added to each well. The plate was then read on a
MesoScale SECTOR imager. Reagents; antibody, read
buffer and calibrators were made up according to
manufacturer’s instructions.
Plaque assay of tumour samples
Tumours were excised from mice that had received
either the cell-based Reovirus vaccine or purified virus
as therapy. Samples were weighed, homogenised and
centrifuged to obtain a clear supernatant. Cell superna-
tants were collected and plaque assayed on L929s as
described previously and expressed as PFU/mg of tissue.
Statistical analysis
Experimental results were plotted and analysed for sig-
nificance with Prism 5 software (GraphPad software Inc.
CA, USA). P < 0.05 was considered significant. Error
bars are representative of (mean + SEM).
Results
Intratumoural treatment of established tumours with
Reovirus alone results in a reduction of tumour burden
and a moderate extension on survival
Mice (n = 5) received purified Reovirus IT in an escalating
dose regimen, twice weekly for three weeks from 1 × 107
PFU to 1 × 109 PFU. A statistically significant increase in
survival was observed in Lewis lung carcinoma-bearing
(LLC) mice (P < 0.05) (Fig. 2b). A moderate increase was
observed in B16F10-bearing mice (n = 5) as compared to
untreated mice (Fig. 2a). Tumour volume of both LLC
and B16F10 showed that there was a delay in the develop-
ment of tumours particularly B16F10 following IT treat-
ment (Fig. 2c, d). Mice received IT Reovirus as soon as
tumours became palpable, B16F10 tumour bearing mice
showed a statistically significant slower rate of tumour
growth compared to untreated mice (P < 0.0001). LLC
tumour-bearing mice also showed a significantly slower
rate of tumour growth in treated mice compared to
untreated (P < 0.05).
Safety and efficacy of a cell-based Reovirus vaccine
Two groups of mice (for each cell line) were inoculated
with a tumourigenic dose of cells. The first group of
C57BL/6J mice had previously received a cell-based Reo-
virus vaccine 8–12 weeks prior to challenge (either
B16F10 vaccine or LLC vaccine as appropriate). No
tumour development was observed in vaccinated mice
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following vaccine administration, B16F10 or LLC. The
second group were naïve mice i.e. unvaccinated. Median
survival of B16F10 injected naive mice was deemed to
be 28 days (n = 5). No tumours were observed in mice
that had previously been “vaccinated” prior to challenge
and survival was beyond 150 days which was deemed to
be curative (P < 0.01) (Fig. 3a). A similar trend was seen
in LLC injected mice (n = 5) where the median survival
of unvaccinated mice was 19 days while vaccinated mice
survived beyond 150 days (P < 0.01) (Fig. 3b). *** To test
the specificity of the vaccine received, mice vaccinated
against B16F10 were inoculated with a tumourigenic
dose of LLC and vice versa. In both instances, tumours
developed and survival was similar to that of unvaccin-
ated and challenged mice (data not shown).
In vitro cytotoxicity and adoptive transfer of lymphocytes
Splenic T lymphocytes obtained from mice vaccinated
with a B16F10-based Reovirus vaccine had increased
cytolytic activity compared to splenocytes obtained from
naïve mice as demonstrated using an MTT-based assay
(Fig. 4a). Cytotoxicity of LLC vaccinated splenocytes was
marginally increased as compared to naïve splenocytes
(Fig. 4b). This increased cytotoxicity for both B16F10
and LLC corresponds to the immunity seen in vivo, as
demonstrated by a modified Winn assay. Groups of mice
(n = 5) received a mixture of B16F10 cells and either
splenocytes from naïve mice or from vaccinated mice,
injected s.c. This was repeated in another group of mice
with LLC cells. Both groups of mice that had received
vaccinated splenocytes from vaccinated mice (B16F10 &
LLC) survived beyond 100 days suggesting a specific im-
munity generated by vaccination (Fig. 4c, d)(P < 0.01).
All mice inoculated with splenocytes from naïve mice
developed tumours, both B16F10 and LLC, whereas no
tumours were observed in mice that had received sple-
nocytes from vaccinated mice for either B16F10 and
LLC (Fig. 4e, f ) (P < 0.0001).
A cell-based vaccine provides a moderate extension on
survival when used as therapy for established tumours
A significant amount of research has been aimed at es-
tablishing a vaccine for cancer or cancer-causing agents
with some success. However, the majority of therapy is
still concerned with eradicating established tumours
[24, 25]. To investigate if a cell-based Reovirus vac-
cine was suitable as a therapy for established tumours
groups of mice (n = 5) received a tumourigenic dose
of B16F10 cells and a tumour was allowed to develop.
The mice were subsequently inoculated with a Reovirus
B16F10-based vaccine either intravenously (IV) through
the tail vein or s.c. Untreated B16F10 bearing mice had a
median survival of 28 days as compared to mice that had
received therapy which had a median survival of 35 days.
Prolonged survival was seen in mice that had received the
vaccine s.c. with a median survival of 39 days (Fig. 5a)
(P < 0.01). This was reflected in the volume of the
tumours where untreated mice had an average tumour
Fig. 2 Treatment of established B16F10 and LLC tumours with purified Reovirus administered IT. a Survival and (c) tumour volume of B16F10
tumours in C57Bl/6j mice (n = 5) following treatment with Reovirus in an escalating dose regimen. b Survival and (d) tumour volume of LLC
tumours following the same regimen in C57Bl/6j mice (n = 5)
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Fig. 4 Cytotoxicity of splenocytes isolated from vaccinated mice. Splenocytes were obtained either from naïve mice or from mice that had been
previously vaccinated (either B16F10 or LLC as appropriate). a and (b) In vitro cytotoxicity of B16F10 and LLC splenocytes from naïve mice and
vaccinated mice against the target cell (B16F10 or LLC as appropriate). Modified Winn assay to determine if the cell-based vaccine could induce
long-term immunity in vivo for B16F10 (c, e) and LLC (d, f). Inoculation groups consisted of (1) target cells (B16F10 or LLC) (2) splenocytes from
naïve mice mixed with target cells and (3) splenocytes from vaccinated mice mixed with target cells
Fig. 3 Challenge of “vaccinated” mice. For both groups (B16F10 and LLC), mice received a cell-based Reovirus vaccine 8–12 weeks prior to day 0.
Survival of (a) B16F10 and (b) LLC vaccinated mice compared to naïve controls. In both incidences vaccinated mice survived beyond 100 days
which was deemed to be curative. Unvaccinated mice developed tumours within 10 days for B16F10 inoculated mice (c) and 7 days for LLC
inoculated (d)
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volume of 1.3cm3 while mice treated with a cell-based
Reovirus vaccine had an average tumour volume of
0.02cm3 and 0.01cm3 for IV and s.c. inoculation respect-
ively (Fig. 5c) (P < 0.0001). A similar trend was seen with
LLC-tumour bearing mice (n = 5) with mice receiving
treatment s.c. demonstrating a moderate increase in sur-
vival, 53 days, compared to the IV group, 50 days. Both
were a significant increase in comparison to the untreated
group which had a median survival of 39 days
(Fig. 5b) (P < 0.001). Tumour volumes of “vaccine”
treated LLC groups were reflective of the increased
survival with the IV group having an average tumour
volume of 0.06cm3 and the s.c. group, 0.03cm3 compared
to 1.2cm3 of the control group (Fig. 5d) (P < 0.0001).
A cell-based Reovirus vaccine is capable of stimulating an
immune response in the tumour microenvironment
The extent of cytokine stimulation or suppression was
evaluated in homogenised tumour samples obtained
from groups of mice that had previously received a cell-
based Reovirus vaccine either IV or s.c. to treat estab-
lished tumours in both B16F10 and LLC models. Neither
mode of administration route appeared to be more
favourable with stimulation varying between the cyto-
kine involved and the origin of the tumour. Subcutane-
ous administration in B16F10 tumour-mice appeared to
have a slightly improved effect in terms of cytokine
stimulation (Fig. 6a). Interferon-γ, Interleukin-12 and
Interleukin-1β, all T helper cell associated cytokines,
demonstrated increased production compared to un-
treated tumours and those that received treatment
Fig. 5 Cell-based Reovirus vaccine for the treatment of established tumours. Survival of (a) B16F10 and (b) LLC-bearing mice subsequent
to treatment with a single dose of cell-based vaccine. Tumour volume of same groups, (c) B16F10 and (d) LLC, showing a significant
delay in tumour development in treated mice
Fig. 6 B16F10 and LLC tumours that had previously received cell-based
Reovirus vaccine as therapy for established tumour were excised and
analysed for cytokine production. Both groups were evaluated – those
that had received the vaccine s.c. and IV. a B16F10 tumours showed no
particular pattern of cytokine production post exposure relative to route
of vaccine administration. b LLC tumours showed a down-regulation of
cytokine levels in almost all evaluated. Statistical significance is indicated
by the stars above each bar (*P< 0.05, **P< 0.01, ***P< 0.0001)
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intravenously. Levels of IL-10 were increased in IV-treated
mice compared to s.c. treated; ideally levels of IL-10
should be suppressed by a successful therapy as regulatory
T cells in the tumour environment often produce IL-10 as
a means of suppressing the immune response to tumour
cells. Conversely, IL-10 levels were suppressed in LLC
tumour bearing mice by both s.c. administration and IV.
Overall, however LLC tumours showed a significant
dampening of cytokine stimulation following treatment
with both IL-12, a significant cytokine in the immune re-
sponse to transformed cells and a mediator between the
innate and adaptive immune system, and TNFα levels
dropping significantly following treatment, both s.c. and
IV (Fig. 6b).
IT administration of purified Reovirus does not
demonstrate an increased cytokine reaction compared to
a cell-based Reovirus vaccine
Cytokine analysis of tumours, both B16F10 and LLC,
that had received Reovirus IT as a means of therapy for
established tumours, did not show a markedly different
level of stimulation or suppression of cytokines as com-
pared to tumours treated with a cell-based Reovirus vac-
cine. Levels of IL-12 remained unchanged in both LLC
and B16F10 tumours although B16F10 tumours showed
stimulation of all other cytokines evaluated while LLC
only showed increased levels of IFNγ and IL-1β com-
pared to untreated controls. LLC tumours did display a
suppression of IL-10 following treatment with the virus
compared to untreated tumours this suppression of IL-
10 was not observed in B16F10 tumours (Fig. 7a, b).
Virus recovery is not indicative of efficacy of treatment
One of the major subjects of debate in virus therapy is
the importance of the presence of replication-competent
virus in the tumour and its environment. Many studies
have indicated that virus titre is not directly proportion-
ate to apoptosis although lack of recovery of active virus
has also been blamed for poor response to viral therapy
[26]. Both LLC and B16F10 tumours that had received
an escalating dose regimen of purified virus IT displayed
a low level of virus recovery following treatment (Fig. 8).
No virus was recovered from tumours that had received
a cell-based Reovirus vaccine as therapy however this
group (vaccine group) showed better survival rates than
those that received virus IT.
Discussion
Cancer vaccination has been the subject of much inves-
tigation as discussed previously. Approaches include a
prophylactic vaccine such as the development of a vac-
cine against Human Papillomavirus (HPV) to prevent
cervical cancer (Gardasil®) or the use of vaccines as ther-
apy for established tumours e.g. the BCG vaccine for
bladder cancer therapy [27]. Both these approaches,
prophylactic and as a therapy for established tumours,
were investigated using a cell-based Reovirus vaccine.
Initial studies of a cell-based Reovirus vaccine showed
great success in the treatment of tumours derived from
both cell lines evaluated; B16F10 and LLC. Animals
Fig. 7 B16F10 and LLC tumours that had previously received purified
Reovirus IT were also evaluated for cytokine production by ELISA.
B16F10 (a) showed a general trend of up-regulation of cytokine
production while no significant changes were observed in LLC
tumours (b) with the exception of IFNγ
Fig. 8 Level of active virus retrieved from treated tumours
approximately one week following cessation of treatment. Active
virus was retrieved from both B16F10 tumours and LLC tumours
that had received purified Reovirus IT. No active virus was retrieved
from tumours treated with the cell-based Reovirus vaccine, either
B16F10 or LLC
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challenged with a tumorigenic dose following only one
vaccination showed inhibition of tumour growth and all
animals survived beyond 100 days. A subsequent modi-
fied Winn assay of splenocytes from vaccinated animals
showed they were capable of preventing tumour estab-
lishment in naïve mice. These results imply that there
is long term immunity to the specific tumour cells in-
volved. While these results are promising, it raises the
question of the feasibility of the use of prophylactic
vaccines, except in rare and specific circumstances. The
vast majority of cancers arise spontaneously hence their
prediction is impossible although certain populations
may benefit such as those predisposed to certain can-
cers e.g. women who carry the defective BRCA1 or
BRCA2 genes which predispose to breast cancer [28].
However they may be applicable in an effort to prevent
metastatic disease which was not evaluated in this
study. Removal of the primary tumour and subsequent
use of a vaccine of this nature, specific for the patient,
may be a feasible approach.
The use of the same vaccine in a therapeutic setting in
the treatment of established tumours also showed some
efficacy with increased rates of survival in all groups.
Therapy by means of the vaccine also demonstrated sig-
nificant delay in the growth of tumours derived from the
cell lines. Subcutaneous administration proved margin-
ally more effective than IV. Administration via the sub-
cutaneous route would potentially allow the virally
infected cells more exposure to antigen presenting cells
(APCs) such as macrophages and dendritic cells which
would not be present in the blood (IV administration),
stimulating the response to Reovirus.
Interestingly, no replication competent virus was re-
trieved from any of the tumours treated with the cell-
based vaccine. Treatment with the vaccine proved to be
more effective in terms of both survival and tumour
volume than tumours treated IT with Reovirus alone
despite the retrieval of virus from IT treated tumours.
It is difficult to determine if the titre of virus in the
tumour is of major importance with reports conflicting
on the significance of high replication levels and its re-
lation to apoptosis induction. Certainly, the results seen
in this study imply that high titres of replication-
competent virus are not necessary for effective therapy
and likewise, increased titres do not translate to sur-
vival benefit.
The immune system plays a major role in cancer by its
initial response in an effort to eliminate tumour cells
and its subsequent failure which allows cancer to pro-
gress [23, 29]. Both B16F10 and LLC tumours exposed
to Reovirus alone showed up-regulation of several
favourable cytokines including Interferon-γ (IFN-γ) and
IL-5 although the cytokines observed and the level of
up-regulation varied between B16F10 and LLC. A
significant increase in the level of IFN-γ was seen in
both lines. IFN-γ has a major role in the activation of
macrophages, cytotoxic T cells and NK cells and is posi-
tive in terms of immune responses to the presence of
tumours. IL-1, a pro-inflammatory cytokine, was also
found to be upregulated in both B16F10 and LLC.
B16F10 tumours treated IT also showed increased
levels of TNFα. TNFα is currently used in the clinic as
immunotherapy [30] and its upregulation leads to the
activation of both macrophages and lymphocytes. The
activation of these cells (macrophages and B cells) may
indicate that both the innate and adaptive immune
response are responsive to the presence of Reovirus al-
though interestingly IL-10 was also increased in B16F10
tumours. IL-10 is often used by tumour cells to suppress
the immune response in order to escape detection [31].
Its presence may indicate that the tumour is making an
effort to down regulate the immune response triggered
by the virus either by producing IL-10 directly or indu-
cing infiltrating immune cells to do so.
IT treated LLC tumours showed a reduction in the
level of IL-10 which should be a favourable outcome
however this did not translate into increased survival.
Few cytokines were substantially up-regulated in LLC
compared to B16F10 with the exception of IL-2 which
was not observed in B16F10 but was noted in LLC (data
not shown) which may have contributed to the variance
in survival rates. IL-2 is another common cytokine in
clinical immunotherapy although its efficacy has been
the subject of much debate. Immunologically, IL-2 trig-
gers T cell proliferation and activates Natural Killer (NK)
cells [23, 32].
A cytokine panel of B16F10 tumours exposed to the
cell-based Reovirus vaccine implies that the mode of ad-
ministration may influence the responses of the immune
system. IV treatment appears to favour cell-mediated re-
sponses with T cell proliferation and lymphocyte and NK
cell activation induced by the cytokines expressed. S.c.
administration favours more inflammatory responses –
IFNγ. In contrast, LLC tumours, regardless of mode of
administration did not show significantly increased
levels of any cytokines evaluated. Despite this, the sur-
vival of both LLC groups – IV and s.c. was significantly
increased compared to B16F10. Other factors, not in-
vestigated here such as tumour lysis syndrome, may
be responsible for the differences observed.
A more extended panel of cytokines or other immuno-
logical factors may reveal other influences. The impres-
sive ability of tumour cells to transform and to influence
the immune system is still a major obstacle in effective
therapy [27] however the responses observed in this
study are promising for the advancement of Reovirus in
the clinic and opens the door for alternative approaches
to virus administration.
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Conclusion
This study demonstrates that the use of a cell-based
Reovirus vaccine is effective in survival prolongation and
immune stimulation and could potentially lead the way
for new advancements in cancer immunotherapy.
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